Xencor, Inc. (NASDAQ:XNCR) Expected to Post Quarterly Sales of $8.15 Million
Wall Street analysts expect Xencor, Inc. (NASDAQ:XNCR) to report sales of $8.15 million for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for Xencor’s earnings, with estimates ranging from $6.00 million to $10.30 million. Xencor posted sales of $7.82 million during the same quarter last year, which would indicate a positive year over year growth rate of 4.2%. The company is scheduled to announce its next quarterly earnings report on Wednesday, November 1st.
According to Zacks, analysts expect that Xencor will report full-year sales of $8.15 million for the current year, with estimates ranging from $18.80 million to $38.30 million. For the next year, analysts forecast that the firm will report sales of $28.10 million per share, with estimates ranging from $20.00 million to $36.20 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of research firms that follow Xencor.
Xencor (NASDAQ:XNCR) last posted its quarterly earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.25) by $0.10. The business had revenue of $13.34 million for the quarter, compared to the consensus estimate of $8.15 million. Xencor had a negative return on equity of 13.79% and a negative net margin of 121.04%.
A number of research firms recently issued reports on XNCR. Canaccord Genuity reissued a “buy” rating and set a $36.00 price target on shares of Xencor in a report on Tuesday. Wedbush reissued an “outperform” rating and set a $29.00 price target on shares of Xencor in a report on Friday, June 16th. Finally, Zacks Investment Research lowered Xencor from a “buy” rating to a “hold” rating in a report on Saturday, April 29th. Four research analysts have rated the stock with a hold rating and four have given a buy rating to the company. Xencor presently has a consensus rating of “Buy” and an average price target of $29.33.
Shares of Xencor (NASDAQ XNCR) opened at 21.28 on Friday. The firm’s 50-day moving average price is $22.64 and its 200 day moving average price is $23.06. The stock’s market cap is $998.59 million. Xencor has a 1-year low of $18.45 and a 1-year high of $29.38.
ILLEGAL ACTIVITY NOTICE: This piece of content was reported by Watch List News and is the sole property of of Watch List News. If you are viewing this piece of content on another site, it was copied illegally and reposted in violation of United States and international copyright law. The correct version of this piece of content can be read at https://www.watchlistnews.com/xencor-inc-nasdaqxncr-expected-to-post-quarterly-sales-of-8-15-million/1471913.html.
In related news, major shareholder John S. Stafford III purchased 1,500 shares of the stock in a transaction that occurred on Friday, June 16th. The shares were purchased at an average price of $19.67 per share, with a total value of $29,505.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, major shareholder John S. Stafford III purchased 6,000 shares of the stock in a transaction that occurred on Wednesday, June 28th. The shares were bought at an average cost of $19.94 per share, for a total transaction of $119,640.00. The disclosure for this purchase can be found here. In the last three months, insiders have sold 34,766 shares of company stock worth $739,408. Corporate insiders own 4.03% of the company’s stock.
Several institutional investors have recently added to or reduced their stakes in the company. Alps Advisors Inc. raised its stake in shares of Xencor by 0.3% in the second quarter. Alps Advisors Inc. now owns 20,102 shares of the biopharmaceutical company’s stock worth $424,000 after buying an additional 52 shares in the last quarter. Falcon Point Capital LLC raised its stake in shares of Xencor by 0.5% in the second quarter. Falcon Point Capital LLC now owns 29,082 shares of the biopharmaceutical company’s stock worth $614,000 after buying an additional 156 shares in the last quarter. Parametric Portfolio Associates LLC raised its stake in shares of Xencor by 0.6% in the first quarter. Parametric Portfolio Associates LLC now owns 36,253 shares of the biopharmaceutical company’s stock worth $867,000 after buying an additional 209 shares in the last quarter. Legal & General Group Plc raised its stake in shares of Xencor by 4.5% in the second quarter. Legal & General Group Plc now owns 8,978 shares of the biopharmaceutical company’s stock worth $189,000 after buying an additional 385 shares in the last quarter. Finally, Clinton Group Inc. raised its stake in shares of Xencor by 4.6% in the first quarter. Clinton Group Inc. now owns 15,987 shares of the biopharmaceutical company’s stock worth $382,000 after buying an additional 700 shares in the last quarter. 74.12% of the stock is currently owned by hedge funds and other institutional investors.
Xencor Company Profile
Xencor, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials and is being developed for autoimmune disease, and XmAb7195, which is in a Phase I trial and is being developed for asthma and allergic diseases.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Xencor Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.